0.5668
price down icon0.58%   -0.0033
 
loading
Schlusskurs vom Vortag:
$0.5701
Offen:
$0.57
24-Stunden-Volumen:
311.56K
Relative Volume:
1.11
Marktkapitalisierung:
$66.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.86M
KGV:
-0.3166
EPS:
-1.79
Netto-Cashflow:
$-125.29M
1W Leistung:
+2.50%
1M Leistung:
-26.86%
6M Leistung:
-28.78%
1J Leistung:
-63.67%
1-Tages-Spanne:
Value
$0.5461
$0.591
1-Wochen-Bereich:
Value
$0.5153
$0.6795
52-Wochen-Spanne:
Value
$0.5153
$2.485

Allovir Inc Stock (ALVR) Company Profile

Name
Firmenname
Allovir Inc
Name
Telefon
(617) 433-2605
Name
Adresse
1100 WINTER STREET, WALTHAM
Name
Mitarbeiter
112
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
ALVR's Discussions on Twitter

Vergleichen Sie ALVR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
ALVR 0.568 66.05M 0 -168.86M -125.29M -1.79
VRTX 450.00 115.43B 10.63B -479.80M -1.35B 13.33
REGN 746.18 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 591.92 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 245.91 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.24 24.89B 3.30B -501.07M 1.03B 11.54

Allovir Inc Stock (ALVR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-10-19 Fortgesetzt Morgan Stanley Overweight
2020-08-24 Eingeleitet JP Morgan Overweight
2020-08-24 Eingeleitet Morgan Stanley Overweight
2020-08-24 Eingeleitet SVB Leerink Outperform

Allovir Inc Aktie (ALVR) Neueste Nachrichten

pulisher
Nov 20, 2024

AlloVir falls after all-stock merger deal with Kalaris - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

AlloVir to combine with Kalaris Therapeutics in all-stock transaction - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

ROSEN, LEADING TRIAL ATTORNEYS, Encourages AlloVir, Inc. Investo - GuruFocus.com

Nov 20, 2024
pulisher
Nov 15, 2024

$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of IPXX, YOTA, IVCP and ALVR - GlobeNewswire Inc.

Nov 15, 2024
pulisher
Nov 15, 2024

AlloVir, Inc. (NASDAQ:ALVR) Sees Significant Drop in Short Interest - MarketBeat

Nov 15, 2024
pulisher
Nov 13, 2024

AlloVir Ditches Immunotherapy, Teams Up with Kalaris to Take Over the $14 Billion Retinal Market - BSA bureau

Nov 13, 2024
pulisher
Nov 12, 2024

Allovir stock plunges to 52-week low of $0.58 amid market challenges - Investing.com India

Nov 12, 2024
pulisher
Nov 12, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire

Nov 12, 2024
pulisher
Nov 12, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, CDMO, EMKR on Behalf of Shareholders - cnhinews.com

Nov 12, 2024
pulisher
Nov 11, 2024

$hareholder Alert: The M&A Class Action Firm Launches Legal Inquiry the Merger ROIC, VINE, ALVR and CDMO - AccessWire

Nov 11, 2024
pulisher
Nov 11, 2024

AlloVir and Kalaris enter merger to advance retinal disease therapies - Pharmaceutical Technology

Nov 11, 2024
pulisher
Nov 11, 2024

AlloVir and Kalaris Therapeutics Announce Merger - FinSMEs

Nov 11, 2024
pulisher
Nov 10, 2024

$hareholder Alert: The M&A Class Action Launches Legal Inquiry for the Merger of ROIC, VINE, ALVR and CDMO - AccessWire

Nov 10, 2024
pulisher
Nov 09, 2024

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc.ALVR - Business Wire

Nov 09, 2024
pulisher
Nov 09, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders - GlobeNewswire

Nov 09, 2024
pulisher
Nov 09, 2024

ROIC, VINE, ALVR and CDMO Alert: The M&A Class Action Firm Continues to Investigate the Merger - AccessWire

Nov 09, 2024
pulisher
Nov 08, 2024

Items Tagged with 'TH-103' - BioWorld Online

Nov 08, 2024
pulisher
Nov 08, 2024

With Eylea rival in clinic, once-stealthy Kalaris finds public path via merger - BioCentury

Nov 08, 2024
pulisher
Nov 08, 2024

Items Tagged with 'Kalaris Therapeutics Inc.' - BioWorld Online

Nov 08, 2024
pulisher
Nov 08, 2024

Allovir sees a new direction with Kalaris merger - BioWorld Online

Nov 08, 2024
pulisher
Nov 08, 2024

SEC Form 425 filed by AlloVir Inc. - Quantisnow

Nov 08, 2024
pulisher
Nov 08, 2024

Kalaris to go public via reverse merger with AlloVir - BioPharma Dive

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir announces merger with Kalaris Therapeutics - The Pharma Letter

Nov 08, 2024
pulisher
Nov 08, 2024

Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian

Nov 08, 2024
pulisher
Nov 08, 2024

ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders - Business Wire

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir and Kalaris Merge to Advance Retinal Therapies - TipRanks

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir and Kalaris Therapeutics To Merge - citybiz

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir Shares Slide Premarket on Reverse Merger With Kalaris Therapeutics - MarketWatch

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir stock falls after Kalaris merger deal (ALVR:NASDAQ) - Seeking Alpha

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina - The Manila Times

Nov 08, 2024
pulisher
Nov 08, 2024

AlloVir and Kalaris Therapeutics Announce Agreement for - GlobeNewswire

Nov 08, 2024
pulisher
Nov 05, 2024

U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.05% - MSN

Nov 05, 2024
pulisher
Nov 02, 2024

Class Action Filed Against AlloVir, Inc. (ALVR) Seeking Recovery for InvestorsContact The Gross Law Firm - GuruFocus.com

Nov 02, 2024
pulisher
Oct 30, 2024

Discovering Opportunities: AlloVir And 2 Other US Penny Stocks - Simply Wall St

Oct 30, 2024
pulisher
Oct 30, 2024

Shareholders that lost money on AlloVir, Inc.(ALVR) Urged to Joi - GuruFocus.com

Oct 30, 2024
pulisher
Oct 30, 2024

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com

Oct 30, 2024
pulisher
Oct 29, 2024

AlloVir (NASDAQ:ALVR) Will Have To Spend Its Cash Wisely - Simply Wall St

Oct 29, 2024
pulisher
Oct 29, 2024

AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors to - GuruFocus.com

Oct 28, 2024
pulisher
Oct 28, 2024

ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Invest - GuruFocus.com

Oct 28, 2024
pulisher
Oct 28, 2024

Respiratory Syncytial Virus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | GSK, MedImmune, ReViral, Pfizer, Sanofi, BioComo, Merck - The Globe and Mail

Oct 28, 2024
pulisher
Oct 28, 2024

SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James - GuruFocus.com

Oct 28, 2024
pulisher
Oct 28, 2024

SHAREHOLDER ALERT: Levi & Korsinsky Notifies AlloVir, Inc.(ALVR) - GuruFocus.com

Oct 28, 2024
pulisher
Oct 28, 2024

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allovir - GuruFocus.com

Oct 28, 2024
pulisher
Oct 25, 2024

Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com

Oct 25, 2024
pulisher
Oct 23, 2024

Allovir CEO Diana Brainard sells $7,596 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Allovir's general counsel Edward Miller sells $1,082 in stock By Investing.com - Investing.com South Africa

Oct 23, 2024
pulisher
Oct 23, 2024

Allovir's general counsel Edward Miller sells $1,082 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Allovir's chief accounting officer Brett Hagen sells $746 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Allovir CFO Vikas Sinha sells $2,649 in stock - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Allovir CFO Vikas Sinha sells $2,649 in stock By Investing.com - Investing.com Canada

Oct 23, 2024

Finanzdaten der Allovir Inc-Aktie (ALVR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):